Targeting of HDAC8 and investigational inhibitors in neuroblastoma

Item Type:	Review
Title:	Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Creators Name:	Oehme, I. and Deubzer, H.E. and Lodrini, M. and Milde, T. and Witt, O.
Abstract:	Histone deacetylase (HDAC) inhibitors are an emerging class of promising novel anticancer drugs. However, little is known which one of the 11 classical HDAC family members is the most relevant drug target for therapy. The first Phase I/II trials show that unselective inhibition of HDACs causes a variety of side effects. Therefore, identification and selective targeting of the most critical tumor entity-relevant HDAC family member may reduce unspecific effects and increase antitumor efficacy in the future. Here, we review the clinical relevance of a particular HDAC family member, HDAC8, in neuroblastoma biology, a highly malignant embryonal childhood cancer. HDAC8 expression correlates with poor outcome in neuroblastoma and selective HDAC8 inhibition induces differentiation. In contrast, the targeting of other HDAC family members results in a completely different phenotype. Because HDAC8-selective inhibitors are available, HDAC8 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
Keywords:	Histone Deacetylase 8, Histone Deacetylase Inhibitor, Isozyme-Selectivity, Neuroblastoma, Animals
Source:	Expert Opinion on Investigational Drugs
ISSN:	1354-3784
Publisher:	Taylor & Francis
Volume:	18
Number:	11
Page Range:	1605-1617
Date:	November 2009
Official Publication:	https://doi.org/10.1517/14728220903241658
PubMed:	View item in PubMed

Repository Staff Only: item control page